Physician profile
Jacqueline Azelvandre
NPI 1639160831
$6,352.44
in general payments reported to CMS, 2019-2025
28 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $1,050 · 2021: $1,167 · 2022: $743 · 2023: $896 · 2024: $740 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,932.13 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $921.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $661.72 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $371.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $362.67 | 2020-2025 | |
| Abbvie INC. | $340.00 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Amarin Pharma, INC. | $253.85 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $240.23 | 2020-2023 | Hetlioz |
| Merck Sharp & Dohme LLC | $229.51 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $194.38 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $129.14 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $123.60 | 2020-2024 | Trelegy Ellipta |
| Abbott Laboratories | $110.45 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $92.49 | 2021-2022 | |
| Amgen INC. | $69.04 | 2019-2025 | Evenity, Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $56.47 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.87 | 2019-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $26.59 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.15 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $26.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.65 | 2019 | |
| Astellas Pharma US INC | $21.60 | 2023 | Veozah |
| Shire North American Group INC | $21.09 | 2019 | |
| Genentech USA, INC. | $16.57 | 2019 | |
| Millicent US INC | $16.44 | 2020 | |
| Bausch Health US, LLC | $14.70 | 2019 | |
| Allergan, INC. | $14.05 | 2019 | |
| Almatica Pharma LLC | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Azelvandre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.